Cortese et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The lancet. Psychiatry. 2018;5:727-738. PMID 30097390¶
One-paragraph summary¶
133 double-blind randomized trials; efficacy and tolerability evaluated by age and outcome rater. (Cortese 2018, PMID 30097390).
Key findings¶
- 133 double-blind randomized trials; efficacy and tolerability evaluated by age and outcome rater.
Limitations¶
- Most endpoints were around 12 weeks; sparse long-term functional evidence.
Why it matters¶
It established the field’s most widely used age-stratified comparative efficacy framework.
Cited by wiki pages¶
- Pharmacologic treatment
- Guidelines
- Attention-deficit/hyperactivity disorder — overview